abstract |
The present invention relates to CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, and gallbladder cancer, and metastases thereof. Provided are anti-CLDN18.2 antibody-drug conjugates that are effective in treating and / or preventing cancer diseases associated with cells expressing. |